PharmaFocus Today – Page 25 – media

ARCH completes $3 billion fundraising! Focus on AI pharmaceuticals

ARCH Venture Partners, an American biotech investment institution, announced the completion of over $3 billion in ARCH Venture Fund XIII fundraising, aimed at supporting the establishment and development of early-stage biotech companies. The 13th fund was established following the 12th fund of $2.975 billion announced in June 2022. “After 38 years, ARCH’s investment philosophy remains the same: we bet on great science and great teams to build breakthrough companies,” said Robert Nelsen, co-founder and managing director of ARCH. “We believe that artificial intelligence and new data-driven insights into biology will help build a more preventive, curative and equitable healthcare system.” “ARCH has a long history of identifying the top forward-looking trends in life science R&D and individuals who drive truly groundbreaking scientific hypotheses,” said Keith Crandell, co-founder and managing director of ARCH. “We are very excited about the pace of innovation and efforts to understand diseases at a deeper level.” ...
- Source: drugdu
- 67
- October 11, 2024
How ciprofloxacin quietly erodes vision

With the popularization of systemic drugs that may affect eye health, it is particularly important to identify the eye side effects caused by drugs. In this medical case analysis, we delved into the diagnosis and treatment process of a 55 year old male patient with toxic optic neuropathy (TON) caused by long-term use of ciprofloxacin. This case provides us with an important warning about the potential impact of drug side effects on the visual system, while also emphasizing the necessity of carefully evaluating drug use history in clinical practice. Medical history summary The patient, male, 55 years old, complained of facial recognition difficulties and decreased reading ability for more than 2 months. Upon examination, it was found that there was a decrease in symmetrical visual acuity, visual field defects, and color vision abnormalities in both eyes. He was diagnosed with TON (usually selectively affecting the optic disc macular bundle). Medical ...
- Source: drugdu
- 71
- October 10, 2024
Nearly 2 billion US dollars! What sparks can be ignited between Shiyao Group and AstraZeneca?

On October 7, 2024, Shiyao Group and AstraZeneca reached a heavyweight cooperation agreement, which caused quite a stir in the pharmaceutical industry. So, let’s explore together in what aspects the cooperation between Shiyao Group and AstraZeneca can spark. Lung cancer product Axitinib In the field of lung cancer treatment, Shiyao Group has achieved outstanding results in the treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations (EGFR ex20ins) by combining humanized EGFR monoclonal antibodies with AstraZeneca’s heavyweight product, Axitinib. The relevant research data was published in Nature Communication and has been widely recognized by the international academic community. At present, the key phase II single arm study for this indication is also being carried out smoothly, and good clinical research data has been obtained. It will be applied for market as soon as possible. Based on this good cooperation result, representatives from both parties signed a cooperation ...
- Source: drugdu
- 74
- October 10, 2024
Investing 22.88 million yuan, leading pharmaceutical company has obtained clinical approval for nuclear drugs!

The board of directors and all directors of our company guarantee that there are no false records, misleading statements or significant omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content. Recently, Tianjin Hengrui Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”), received approval from the National Medical Products Administration (hereinafter referred to as the “NMPA”) to issue a “Drug Clinical Trial Approval Notice” for fluoride [18F] metoprolol injection, and will conduct clinical trials in the near future. Basic information of drugs Drug Name: Fluorine [18F] Metoprolol Injection Form: Injection Application Matters: Clinical Trial Acceptance Number: CYHL2400142 Approval Conclusion: According to the Drug Administration Law of the People’s Republic of China and relevant regulations, after examination, the Fluorine [18F] Metoprolol Injection accepted on July 9, 2024 meets the relevant requirements for ...
- Source: drugdu
- 85
- October 10, 2024
Nearly 2 billion US dollars! What sparks can be ignited between CSPC and AstraZeneca?

Lung cancer product Axitinib In the field of lung cancer treatment, CSPC has achieved outstanding results in the treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations (EGFR ex20ins) by combining humanized EGFR monoclonal antibodies with AstraZeneca’s heavyweight product, Axitinib. The relevant research data was published in Nature Communication and has been widely recognized by the international academic community. At present, the key phase II single arm study for this indication is also being carried out smoothly, and good clinical research data has been obtained. It will be applied for market as soon as possible. Based on this good cooperation result, representatives from both parties signed a cooperation agreement in order to continue the collaboration in the Phase III confirmatory study of this indication. Chen Kangwei, General Manager of AstraZeneca China Oncology Division, stated that the strategic cooperation between the two parties is through a strong alliance ...
- Source: drugdu
- 89
- October 10, 2024
Latest! AstraZeneca announces 10 billion yuan cooperation

On October 7, AstraZeneca and CSPC Pharmaceutical Group signed an exclusive licensing agreement, and AstraZeneca will obtain CSPC Pharmaceutical Group’s preclinical candidate small molecule drug YS2302018. The transaction amount hit a new high. According to the agreement, CSPC Pharmaceutical Group will receive an advance payment of US$100 million and is entitled to receive potential development milestone payments of up to US$370 million and potential sales milestone payments of up to US$1.55 billion, as well as tiered sales commissions calculated based on the annual net sales of the product (the total transaction amount exceeds RMB 10 billion at the current exchange rate). YS2302018 is a preclinical innovative small molecule lipoprotein (a) (Lp(a)) inhibitor used to develop new lipid-lowering therapies, as well as monotherapy or combination therapy for a variety of cardiovascular diseases, including in combination with the oral small molecule PCSK9 inhibitor AZD0780. Lpa is an important target in the field ...
- Source: drugdu
- 79
- October 10, 2024
Domestic substitution has entered the sprint period, where is the key?

As one of the hottest terms in 2024, “new quality productivity” is not only an upgrade of economic terms, but also a reflection of the process of era change, hiding the pulse of future industrial development. In many reports and documents issued by the state this year, the field of life sciences is closely linked to new quality productivity. At present, Beijing, Shanghai, Guangdong, Chongqing, Zhejiang, Jiangsu and other provinces and cities have successively issued documents to promote the development of new quality productivity and detailed implementation. At present, the field of life sciences is in a period of rapid change, showing unprecedented vitality. After returning to China after studying abroad, many outstanding scholars have greatly promoted the development of this field, especially the development of basic medical research, biotechnology innovation, biopharmaceuticals, clinical diagnosis and treatment. The development is particularly prosperous. Although the medical industry is treacherous, the rules are ...
- Source: drugdu
- 63
- October 10, 2024
Let’s go to Europe to seek gold

It is a general trend for pharmaceutical companies to go overseas, and the proposition of the times behind it is also advancing with the times. Under the new changes, how to re-examine the gold-mining places such as the United States, Europe, and Southeast Asia? Different countries and regions have different market sizes and policies and regulations. How to examine the pros and cons of the market and formulate a more suitable strategy for going overseas? Everything needs to be answered by the industry. At present, more and more signs show that pharmaceutical companies are no longer just focusing on the “fat meat” of the US market as in the past, and countries and regions such as Europe are becoming more and more important. After being hit repeatedly by the FDA, more and more PD-1s have moved to Europe and been approved for listing. Since the beginning of this year, domestic ...
- Source: drugdu
- 76
- October 10, 2024
Merger of two well-known pharmaceutical companies

On October 7, Jiahe Bio announced that it would acquire Yitong Pharmaceuticals by merger. The name of the merged company will be changed to Yitong Jiahe Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Yitong Jiahe”). The transaction is carried out in the form of a share swap. The price of the proposed merger will be fully settled by issuing consideration shares. After the merger is completed, the shareholders of both parties will jointly hold the equity of Yitong Jiahe, and Jiahe Bio will not have any cash expenditure. According to the listing rules, the transaction constitutes a reverse acquisition of Jiahe Bio. In the merged Yitong Jiahe, the original Yitong Pharmaceutical shareholders accounted for 77.43%, and the original Jiahe Bio shareholders accounted for 22.57%. The actual controller of Yitong Pharmaceutical will become the controlling shareholder of Yitong Jiahe. Based on the rules of Chapter 18A of the Hong Kong ...
- Source: drugdu
- 69
- October 10, 2024
PCSK9 antibody marketing application received notification

On September 29, 2024, two acceptance numbers for Junshi Biosciences’s PCSK9 antibody marketing application were notified, indicating that they have not been approved (possibly due to voluntary withdrawal or pending approval). In April 2023, Junshi Biosciences received 4 acceptance numbers for its PCSK9 antibody market application, of which 2 were notified this time, and the other 2 have not yet received results. Four acceptance numbers involve two specifications (pre filled syringes, pre filled automatic syringes) and two indications. This two notifications indicate that a certain specification or indication has not been approved. The competition for PCSK9 targets is particularly fierce. In addition to antibodies from Amgen and Sanofi, PCSK9 antibodies from Sinovac Biotech and PCSK9 siRNA from Novartis have already been approved for marketing. Among them, Novartis’ PCSK9 siRNA only needs to be administered once every six months. For this target, there are more differentiated products under development, including Merck’s ...
- Source: drugdu
- 73
- October 9, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.